Home Categories Send inquiry

Zoledronic Acid Monohydrate CAS 165800-06-6 Purity ≥99.0% API Factory High Purity

Manufacturer with High Purity and Stable Quality Chemical Name: Zoledronic Acid Monohydrate CAS: 165800-06-6 A highly potent bisphosphonate and activator of PKC API High Quality, Commercial Production
Chemical Name Zoledronic Acid Monohydrate
CAS Number 165800-06-6
CAT Number RF-API56
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C5H12N2O8P2
Molecular Weight 290.1
Brand Ruifu Chemical
Item Specifications
Appearance White or Almost Crystalline Powder
Identification IR spectrum HPLC chromatogram UV-Vis: There is a maximum absorbance at 210nm
pH 2.0~4.0
Clarity and Color Comply with requirements
Single Impurity ≤0.50%
Total Impurities ≤1.0%
Loss on Drying 5.0%~8.0%
Chloride ≤0.02%
Phosphate ≤0.50%
Phosphite ≤0.50%
Heavy Metals ≤10ppm
Purity ≥99.0%
Test Standard Enterprise Standard
Usage API
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation. Zoledronic acid monohydrate is a highly potent bisphosphonate and activator of PKC.Zoledronic acid monohydrate is a heterocyclic bisphosphonate that is considered to have the highest potency of bisphosphonates for suppression of increased bone resorption and has been used in several osteoporosis studies. The compound has been observed to be more effective than pamidronate (sc-203178). Zoledronic acid has been used in studies investigating mesothelioma. Zoledronic acid monohydrate is an inhibitor of ASM and FDPS and an activator of PKC. Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. It has been used to treat postmenopausal osteoporosis, Paget's disease, hypercalcemia, and along with cancer chemotherapy to treat bone damage caused by cancer that has spread to the bones.